Abstract: A system includes a secure, in-memory unit implemented on an associative processing unit (APU) for performing a secure similarity search. The unit implements a decryptor, an encoded vector store and a similarity searcher. The decryptor decrypts an encrypted, encoded vector into an encoded vector. The encoded vector data store stores a plurality of encoded search candidate vectors. The similarity searcher performs a similarity search between an encoded search query vector and the plurality of encoded search candidate vectors.

Abstract: An environmental DNA (eDNA) sensor and associated methods of detecting eDNA are disclosed. The eDNA sensor comprises a sample capture module configured to capture a fluid sample from a marine environment; a DNA extraction module fluidly coupled to the sample capture module and configured to extract and purify DNA captured by the sample capture module; and a genetic analysis module fluidly coupled to the DNA extraction module for analyzing the DNA to detect a target species. The eDNA sensor enables real-time, autonomous, and in-situ eDNA collection, extraction, purification, and detection. The sensor and methods can also be applied for environmental RNA (eRNA) detection.

Abstract: A system includes a secure, in-memory unit implemented on an associative processing unit (APU) for performing a secure similarity search. The unit implements a decryptor, a neural proxy hash encoder, an encoded vector store and a similarity searcher. The decryptor decrypts an encrypted data vector into a data vector. The neural proxy hash encoder encodes the data vector into an encoded search data vector. The encoded vector data store stores a plurality of encoded search candidate vectors and the similarity searcher performs a similarity search between an encoded search query vector and the plurality of encoded search candidate vectors.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: A system including a secure, in-memory unit implemented on an associative processing unit (APU), for creating encrypted vectors. The in-memory unit includes a data store and an encryptor. The data store stores data and the encryptor encrypts the data into an encrypted vector. Optionally, the unit includes a neural proxy hash encoder that encodes the data into an encoded vector, and, in this embodiment, the encryptor encrypts the encoded vector into an encrypted encoded vector. The neural proxy hash encoder includes a trained neural network which includes a plurality of layers that encode the data into feature sets. The trained neural network encodes image files, audio files, or large data sets. The APU is implemented on SRAM, non-volatile, or non-destructive memory.

Abstract: Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: A cart for medical equipment includes a base having one or more wheels, a column supported by the base, and a platform supported on the column and opposite the base. The platform is configured to mount a piece of medical equipment to the cart. The cart also includes an adapter plate securable to the piece of medical equipment and configured to releasably couple to the platform. The adapter plate includes a locking assembly having one or more handles that upon actuation releases the adapter plate from the platform.

Abstract: The present invention relates to systems and methods of express tracking for patient flow management in a distributed environment. Particularly, aspects are directed to a computer implemented method that includes initiating a check-in process that includes prompting a user to scan an identifier, processing the identifier using a cascade machine-learning architecture comprising of a multi-task convolutional neural network model and a recurrent neural network model to obtain the classification of the identifier and member identification information, determining whether the user is known user based on the member identification information, when the user is a known user, verifying user data saved in the computing system associated with the identifier, once the user data is verified, determining whether the user has a scheduled appointment; and when the user has a scheduled appointment, checking the user in for the scheduled appointment.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: A cart for medical equipment includes a column supporting a platform for mounting a piece of medical equipment to the cart. A base including one or more wheels that support the column, and a handgrip at least partially encircling the platform. The handgrip includes an upper surface substantially devoid of openings and an opposite lower surface including one or more elongated accessory slots opening downwardly toward the one or more wheels. The one or more elongated accessory slots are configured to receive a portion of an accessory mount such that the accessory mount is slidingly adjustable along a length of the one or more accessory slots.

Abstract: A cart for medical equipment includes a base having one or more wheels, a column supported by the base, and a platform supported on the column and opposite the base. The platform is configured to mount a piece of medical equipment to the cart. The cart also includes an adapter plate securable to the piece of medical equipment and configured to releasably couple to the platform. The adapter plate includes a locking assembly having one or more handles that upon actuation releases the adapter plate from the platform.

Abstract: The present invention relates to systems and methods of express tracking for patient flow management in a distributed environment. Particularly, aspects are directed to a computer implemented method that includes initiating a check-in process that includes prompting a user to scan an identifier, processing the identifier using a cascade machine-learning architecture comprising of a multi-task convolutional neural network model and a recurrent neural network model to obtain the classification of the identifier and member identification information, determining whether the user is known user based on the member identification information, when the user is a known user, verifying user data saved in the computing system associated with the identifier, once the user data is verified, determining whether the user has a scheduled appointment; and when the user has a scheduled appointment, checking the user in for the scheduled appointment.

Abstract: The present invention relates to systems and methods of express tracking for patient flow management in a distributed environment. Particularly, aspects are directed to a computer implemented method that includes initiating a check-in process that includes prompting a user to scan an identifier, processing the identifier using a cascade machine-learning architecture comprising of a multi-task convolutional neural network model and a recurrent neural network model to obtain the classification of the identifier and member identification information, determining whether the user is known user based on the member identification information, when the user is a known user, verifying user data saved in the computing system associated with the identifier, once the user data is verified, determining whether the user has a scheduled appointment; and when the user has a scheduled appointment, checking the user in for the scheduled appointment.

Abstract: A cart for medical equipment includes a base having one or more wheels, a column supported by the base, and a platform supported on the column and opposite the base. The platform is configured to mount a piece of medical equipment to the cart. The cart also includes an adapter plate securable to the piece of medical equipment and configured to releasably couple to the platform. The adapter plate includes a locking assembly having one or more handles that upon actuation releases the adapter plate from the platform.

Abstract: Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: A cart for medical equipment includes a column supporting a platform for mounting a piece of medical equipment to the cart. A base including one or more wheels that support the column, and a handgrip at least partially encircling the platform. The handgrip includes an upper surface substantially devoid of openings and an opposite lower surface including one or more elongated accessory slots opening downwardly toward the one or more wheels. The one or more elongated accessory slots are configured to receive a portion of an accessory mount such that the accessory mount is slidingly adjustable along a length of the one or more accessory slots.